DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934 (Amendment No.                )

 

 

Filed by the Registrant  ☒                            Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material under §240.14a-12

AERPIO PHARMACEUTICALS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

  No fee required.
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1)  

Title of each class of securities to which transaction applies:

 

    

  (2)  

Aggregate number of securities to which transaction applies:

 

    

  (3)  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

    

  (4)  

Proposed maximum aggregate value of transaction:

 

    

  (5)  

Total fee paid:

 

    

  Fee paid previously with preliminary materials.
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  (1)  

Amount Previously Paid:

 

    

  (2)  

Form, Schedule or Registration Statement No.:

 

    

  (3)  

Filing Party:

 

    

  (4)  

Date Filed:

 

    

 

 

 


 

 

     LOGO

AERPIO PHARMACEUTICALS, INC.

9987 CARVER ROAD, SUITE 420

CINCINNATI, OH 45242

D55846-P58752

 

 

LOGO

LOGO

 

 

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on July 22, 2021.

You invested in AERPIO PHARMACEUTICALS, INC. and it’s time to vote!

You have the right to vote on proposals being presented at the Annual Meeting.

Get informed before you vote

View the Notice, Proxy Statement and 2020 Annual Report online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to July 8, 2021. If you would like to request a copy of the material(s) for this and/ or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 (toll-free from the U.S., U.S. territories and Canada) or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

 

 

LOGO

 

Smartphone users

 

      LOGO   

Vote Virtually at the Meeting*

Point your camera here and       July 22, 2021
vote without entering a       10:30 AM EDT
control number      

LOGO

 

     

 

Virtually at:

www.virtualshareholdermeeting.com/ARPO2021

                       
          

 

 

 

  *

Please check the meeting materials for any special requirements for meeting attendance.

V1


Vote at www.ProxyVote.com

 

 

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming annual meeting of stockholders. Please follow the instructions on the reverse side to vote on these important matters.

 

 

                     Board
    Voting Items            Recommends
 
     1.   To elect two Class I directors to hold office until the 2024 annual meeting of stockholders:   
 
    Nominees:             LOGO For
    01)   Caley Castelein, M.D.         
        02)   Cheryl Cohen             
     2.   To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.    LOGO For

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

          
          
          
          
          

 

 

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”.

 

D55847-P58752